Calder Biosciences

Calder Biosciences is a private, preclinical-stage biotech applying its novel 3D-Vaxlock™ protein engineering platform to develop best-in-class vaccines. The platform introduces targeted, covalent dityrosine crosslinks to 'lock' viral immunogens in their most potent prefusion shape, aiming to elicit stronger and more protective immune responses. Initial pipeline targets include RSV and a universal influenza vaccine, with the goal of improving efficacy, durability, and thermostability over existing options. The company emphasizes a de-risked approach by engineering solutions for well-characterized viral targets rather than pursuing de novo discovery.

3D-Vaxlock™: A proprietary protein engineering platform that uses structure-based design to introduce site-specific, covalent dityrosine crosslinks into viral immunogens, locking them in their potent prefusion 3D conformation to elicit superior protective immune responses.

In RSV, Calder faces competition from recently approved vaccines by GSK, Pfizer, and others, plus pipeline candidates. In influenza, the competitive field includes major vaccine manufacturers (Sanofi, Seqirus) and numerous biotechs pursuing universal flu vaccines, making differentiation on efficacy and breadth critical.